ImmunityBio, Inc.IBRXEarnings & Financial Report

Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)

Deep AnalysisCompare

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.